- Trials with a EudraCT protocol (27)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
27 result(s) found for: Androgen Deficiency.
Displaying page 1 of 2.
EudraCT Number: 2010-021790-37 | Sponsor Protocol Number: UK_S-H_08_0006 | Start Date*: Information not available in EudraCT | |||||||||||
Sponsor Name:Universitätsklinikum Schleswig-Holstein, Campus Lübeck | |||||||||||||
Full Title: Comparison of clinical and metabolic effects of testosterone and estradiol in adult gonadectomized patients with 46,XY DSD due to complete androgen insensitivity syndrome (CAIS) | |||||||||||||
Medical condition: The medical condition under investigation is complete androgen insensitivity syndrome (CAIS) in gonadectomized patients with 46,XY karyotype due to mutations of the androgen receptor, which lead to... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Female | ||||||||||||
Trial protocol: DE (Completed) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2018-004802-24 | Sponsor Protocol Number: NL68556.091.18 | Start Date*: 2019-05-20 |
Sponsor Name:Radboud University Nijmegen Medical Centre | ||
Full Title: Optimizing timing of glucocorticoid treatment in children with congenital adrenal hyperplasia | ||
Medical condition: Congenital adrenal hyperplasia (CAH) is a disorder of adrenal steroid synthesis leading to cortisol deficiency and an increase in androgen production.Treatment in children consists of hydrocortis... | ||
Disease: | ||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | |
Trial protocol: NL (Completed) | ||
Trial results: View results |
EudraCT Number: 2011-004266-15 | Sponsor Protocol Number: ARYHM-1 | Start Date*: 2012-01-18 | |||||||||||
Sponsor Name:RMC, Skåne University Hospital | |||||||||||||
Full Title: Androgen replacement in young hypogonadal men: a 2 year randomized, double-blind placebo controlled study | |||||||||||||
Medical condition: Target population: Male hypogonadism (testosterone deficiency) As end points Bone mineralisation Body composition Markers of insulin sensitivity and cardiovascular disease Lipid profile H... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: SE (Ongoing) NO (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-004430-96 | Sponsor Protocol Number: 201600107 | Start Date*: 2017-12-11 |
Sponsor Name:University Medical Center Groningen | ||
Full Title: Short-term Testosterone replacement in testicular cancer survivors to treat overweight and improve cardiometabolic risk | ||
Medical condition: Testicular cancer | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2018-002587-28 | Sponsor Protocol Number: BGB-290-202 | Start Date*: 2019-08-30 | ||||||||||||||||
Sponsor Name:BeiGene, Ltd. | ||||||||||||||||||
Full Title: A Phase 2, Open-Label, Single-Arm Study of Pamiparib (BGB-290) for the Treatment of Patients with Metastatic Castration-Resistant Prostate Cancer (mCRPC) with Homologous Recombination Deficiency (HRD) | ||||||||||||||||||
Medical condition: Patients with metastatic castration-resistant prostate cancer (mCRPC) positive for circulating tumor cells (CTC) with homologous recombination deficiency | ||||||||||||||||||
|
||||||||||||||||||
Population Age: Adults, Elderly | Gender: Male | |||||||||||||||||
Trial protocol: GB (Prematurely Ended) ES (Completed) | ||||||||||||||||||
Trial results: View results |
EudraCT Number: 2015-000458-40 | Sponsor Protocol Number: Infacort004 | Start Date*: 2015-10-20 |
Sponsor Name:Diurnal Limited | ||
Full Title: Open-label, long-term follow-up of safety and biochemical disease control of Infacort® in neonates, infants and children with congenital adrenal hyperplasia and adrenal insufficiency previously enr... | ||
Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. ... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2012-000870-51 | Sponsor Protocol Number: CMCS240281 | Start Date*: 2013-02-25 |
Sponsor Name:Unidad de Gestión Clínica de Endocrinología y Nutrición | ||
Full Title: RANDOMIZED CLINICAL TRIAL TO ASSESS THE EFFICACY OF TESTOSTERONE UNDECANOATE, METFORMIN, OR THE COMBINATION OF BOTH, FOR THE TREATMENT OF ISOLATED HYPOGONADOTROPIC HYPOGONADISM AND ERECTILE DYSFUNC... | ||
Medical condition: Isolated hypogonadotropic hypogonadism related to obesity | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: ES (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-005938-15 | Sponsor Protocol Number: CloTASH-2021-2Version15.10.21 | Start Date*: 2021-11-03 |
Sponsor Name:Oslo University Hospital | ||
Full Title: Health risks and treatment of anabolic-androgenic steroid (AAS) induced hypogonadism among men – a pilot study exploring off-label use of clomiphene citrate to reduce symptoms of androgen deficienc... | ||
Medical condition: Anabolic androgenic steroid induced hypogonadism among men | ||
Disease: | ||
Population Age: Adults | Gender: Male | |
Trial protocol: NO (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2020-004381-19 | Sponsor Protocol Number: NBI-74788-CAH2006 | Start Date*: 2021-06-07 | |||||||||||
Sponsor Name:Neurocrine Biosciences, Inc. | |||||||||||||
Full Title: A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Crinecerfont (NBI-74788) in Pediatric Subjects with Classic Congenital Adrenal Hyperplasia, Followed by O... | |||||||||||||
Medical condition: Classic Congenital Adrenal Hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Children, Adolescents, Under 18 | Gender: Male, Female | ||||||||||||
Trial protocol: GR (Ongoing) DE (Completed) FR (Ongoing) PL (Ongoing) BE (Ongoing) ES (Ongoing) IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-000711-40 | Sponsor Protocol Number: DIUR-005 | Start Date*: 2015-11-19 | |||||||||||
Sponsor Name:Diurnal Ltd | |||||||||||||
Full Title: A Phase III study of efficacy, safety and tolerability of Chronocort® compared with standard glucocorticoid replacement therapy in the treatment of congenital adrenal hyperplasia. | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (Completed) DE (Completed) SE (Completed) NL (Completed) DK (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2014-002265-30 | Sponsor Protocol Number: Infacort003 | Start Date*: 2015-02-19 |
Sponsor Name:Diurnal Limited | ||
Full Title: A Phase 3 open-label study of Infacort® in neonates, infants and children less than 6 years of age with adrenal insufficiency. | ||
Medical condition: Adrenal Insufficiency (AI) in children is most commonly due to Congenital Adrenal Hyperplasia (CAH) and results in cortisol deficiency with or without aldosterone deficiency and androgen excess. Cu... | ||
Disease: | ||
Population Age: Newborns, Infants and toddlers, Children, Under 18 | Gender: Male, Female | |
Trial protocol: DE (Completed) | ||
Trial results: View results |
EudraCT Number: 2006-006925-26 | Sponsor Protocol Number: no sponsor | Start Date*: 2007-04-05 |
Sponsor Name:Rijnstate hospital | ||
Full Title: Optimalising the Androgen-Oestrogen Balance in Testosterone Substituted Hypogonadal Men by Aromatase Inhibition. | ||
Medical condition: Men with hypogonadotropic hypogonadism treated with testosterone substitution | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: NL (Ongoing) | ||
Trial results: (No results available) |
EudraCT Number: 2015-005760-42 | Sponsor Protocol Number: MBGS205 | Start Date*: 2016-05-25 | |||||||||||
Sponsor Name:Mereo BioPharma 2 Limited | |||||||||||||
Full Title: A Phase IIb multicentre, double-blind, dose-ranging, randomised, placebo-controlled study evaluating safety and efficacy of BGS649 in male obese subjects with hypogonadotropic hypogonadism | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism (HH) | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: GB (Completed) ES (Completed) IT (Completed) | |||||||||||||
Trial results: View results |
EudraCT Number: 2004-001545-15 | Sponsor Protocol Number: 307720 | Start Date*: 2004-11-04 |
Sponsor Name:Schering AG | ||
Full Title: Estudio multicéntrico, doble ciego, aleatorizado, controlado con placebo de Testogel® (testosterona 50–100mg) para evaluar su eficacia y seguridad en hombres que presentan síntomas típicos de defic... | ||
Medical condition: Déficit Androgénico parcial en la edad avanzada. | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: ES (Completed) IE (Completed) | ||
Trial results: View results |
EudraCT Number: 2017-001553-14 | Sponsor Protocol Number: BGB-290-103 | Start Date*: 2018-06-29 |
Sponsor Name:BeiGene USA, Inc. | ||
Full Title: A Phase 1b Study to Assess the Safety, Tolerability, and Clinical Activity of BGB-290 in Combination with Temozolomide (TMZ) in Subjects with Locally Advanced or Metastatic Solid Tumors | ||
Medical condition: Locally Advanced or Metastatic Solid Tumors (ovarian cancer, triple negative breast cancer (TNBC), metastatic castration-resistant prostate cancer (mCRPC), small cell lung cancer (SCLC), and gastri... | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male, Female | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: View results |
EudraCT Number: 2012-001258-25 | Sponsor Protocol Number: MK8962-031-00 | Start Date*: 2012-11-29 | |||||||||||
Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. | |||||||||||||
Full Title: A phase III, multi-center, open label, uncontrolled trial to investigate the efficacy and safety of MK-8962 (corifollitropin alfa) in combination with human Chorionic Gonadotropin (hCG) in inducing... | |||||||||||||
Medical condition: Hypogonadotropic hypogonadism (HH) in males may result from either absent or inadequate gonadotropin-releasing hormone (GnRH) secretion by the hypothalamus or failure of pituitary gonadotropin secr... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: DE (Completed) ES (Completed) IT (Completed) GB (Completed) PL (Completed) Outside EU/EEA | |||||||||||||
Trial results: View results |
EudraCT Number: 2019-004677-12 | Sponsor Protocol Number: RHYTHM | Start Date*: 2021-02-09 | |||||||||||
Sponsor Name:UNIVERSITA' DEGLI STUDI DI MODENA E REGGIO EMILIA - DIPARTIMENTO DI SCIENZE BIOMEDICHE, METABOLICHE E NEUROSCIENZE | |||||||||||||
Full Title: Pharmacodynamics and safety of human recombinant luteinising hormone in hypogonadotropic hypogonadal men. | |||||||||||||
Medical condition: Aquired hypogonadotropic hypogonadism | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male | ||||||||||||
Trial protocol: IT (Ongoing) | |||||||||||||
Trial results: (No results available) |
EudraCT Number: 2015-005448-32 | Sponsor Protocol Number: DIUR-006 | Start Date*: 2016-07-20 | |||||||||||
Sponsor Name:Diurnal Ltd | |||||||||||||
Full Title: A Phase III extension study of efficacy, safety and tolerability of Chronocort® in the treatment of congenital adrenal hyperplasia (CAH) | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH); is generally due to 21-hydroxylase deficiency, is a disease of the adrenal cortex characterised by cortisol deficiency with or without aldosterone deficiency, ... | |||||||||||||
|
|||||||||||||
Population Age: Adults | Gender: Male, Female | ||||||||||||
Trial protocol: GB (GB - no longer in EU/EEA) SE (Completed) DE (Completed) DK (Prematurely Ended) | |||||||||||||
Trial results: View results |
EudraCT Number: 2011-006114-14 | Sponsor Protocol Number: 62326B1658 | Start Date*: 2012-04-17 |
Sponsor Name:Research and Development department | ||
Full Title: “Effects of testosterone on glycaemic control and other Cardiovascular Risk factors in Hypogonadal Men with uncontrolled Type 2 Diabetes: A randomized double – blinded placebo controlled add on tr... | ||
Medical condition: Hypogonadism Type 2 Diabetes Cardiovascular risk | ||
Disease: | ||
Population Age: Adults, Elderly | Gender: Male | |
Trial protocol: GB (GB - no longer in EU/EEA) | ||
Trial results: (No results available) |
EudraCT Number: 2011-005822-23 | Sponsor Protocol Number: REK231814 | Start Date*: 2012-10-16 | |||||||||||
Sponsor Name:Haukeland University Hospital | |||||||||||||
Full Title: CONTINUOUS SUBCUTANEOUS HYDROCORTISONE INFUSION IN CONGENITAL ADRENAL HYPERPLASIA | |||||||||||||
Medical condition: Congenital adrenal hyperplasia (CAH) | |||||||||||||
|
|||||||||||||
Population Age: Adolescents, Under 18, Adults | Gender: Male, Female | ||||||||||||
Trial protocol: NO (Ongoing) SE (Completed) | |||||||||||||
Trial results: (No results available) |
Subscribe to this Search
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here . This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
Download Options: | |
---|---|
Number of Trials to download: | |
Download Content: | |
Download Format: | |
Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. |
Query did not match any studies.